We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avanir Settles With Wockhardt Over Nuedexta, Generic Entry
Avanir Settles With Wockhardt Over Nuedexta, Generic Entry
September 24, 2013
Avanir Pharmaceuticals said Sept. 6 it has entered into a settlement agreement granting Wockhardt the right to sell a generic of Nuedexta before its last protective patent expires on Aug. 15, 2026.